Skip to main content

The independent source for health policy research, polling, and news.

Subscribe Follow Us Donate
  • Trump 2.0

    Trump 2.0

    • Agency Watch
    • State Watch
    • Rural Health Payout
  • Public Health

    Public Health

    • Vaccines
    • CDC & Disease
    • Environmental Health
  • Audio Reports

    Audio Reports

    • What the Health?
    • Health Care Helpline
    • KFF Health News Minute
    • An Arm and a Leg
    • Health Hub
    • HealthQ
    • Silence in Sikeston
    • Epidemic
    • See All Audio
  • Special Reports

    Special Reports

    • Bill Of The Month
    • The Body Shops
    • Broken Rehab
    • Deadly Denials
    • Priced Out
    • Dead Zone
    • Diagnosis: Debt
    • Overpayment Outrage
    • Opioid Settlement Tracking
    • See All Special Reports
  • More Topics

    More Topics

    • Elections
    • Health Care Costs
    • Insurance
    • Prescription Drugs
    • Health Industry
    • Immigration
    • Reproductive Health
    • Technology
    • Rural Health
    • Race and Health
    • Aging
    • Mental Health
    • Affordable Care Act
    • Medicare
    • Medicaid
    • Children’s Health

  • Medicaid Work Requirements
  • ‘Skinny Labeling’
  • Gun Control
  • Suicide Prevention
  • Rural Health Payout

TRENDING TOPICS:

  • Medicaid Work Requirements
  • 'Skinny Labeling'
  • Gun Control
  • Suicide Prevention
  • Rural Health Payout

Morning Briefing

Summaries of health policy coverage from major news organizations

  • Email

Wednesday, May 13 2020

Full Issue

Perspectives: That Government Can't Regulate Vaccine Price Is Lie Americans Have Been Living With For Decades

Read recent commentaries about drug-cost issues.

Newsweek: Yes, The Government Can Control The Cost Of A Coronavirus Vaccine

When I was diagnosed at age 32 with ALS, a debilitating disease that would give me a life expectancy of three to four years, my ability to access medicine became a matter of life and death. That's true for millions of Americans who rely on one or more drugs to stay alive. But something unusual is happening in our medical system today. Right now, there is one prescription drug that every single American needs urgently: a vaccine for the coronavirus. It's rare that the need for one drug can be so universal—so crucial to the health of everyone in the country, the health of the economy and the very stability of our society. (Ady Barkan, 5/7)

Stat: The Public Role In Drug Development: Lessons From Remdesivir 

The quest for vaccines and therapeutic treatments against Covid-19 shouldn’t be complicated or delayed by charged debates over patent rights, the respective public and private roles in biopharmaceutical innovation, and whether the U.S. government should use its legal powers to “break” patents in order to promote access to medicines. But it may be. Gilead’s antiviral drug remdesivir, for which the FDA recently granted emergency use authorization for Covid-19, is currently caught in the crosshairs of the debate. We suggest a path forward that could be useful in the remdesivir case and in others. (Justin Hughes and Ati K. Rai, 5/8)

Capital Gazette: Hogan Adds Insult To Injury With Veto Of Maryland Drug Affordability Act

You may not agree with Gov. Larry Hogan on business shut-downs and phased opening plans, but he has been calm and effective. He has demonstrated real concern for the health of Marylanders. Social distancing and other policies have helped Maryland avert a disaster similar to New York’s. Regardless, daily counts of new cases and deaths fluctuate, numbers were higher again last week after three days of decreasing numbers. It is alarming to see that Maryland just misses being in the top 10 states for total number of cases and is 10th in the number of deaths. (Janet Holbrook, 5/12)

Forbes: Safeguarding And Streamlining Pharma Supply Chain: Time For Mandating Certified Drugs

US pharmaceutical spending during the year 2020, is expected to top $400 billion. Americans spend about $1,200 on prescription drugs per year, the highest in the developed world. Generics are a critical cost reduction component of pharma spending; saving a whopping $2 trillion in the past ten years. 90% of the prescriptions are dispensed with generics, yet they account for only 26% of the drug spending. Without generic drugs, most private and public health programs would be cost-prohibitive. (Roomy Khan, 5/7)

This is part of the Morning Briefing, a summary of health policy coverage from major news organizations. Sign up for an email subscription.
Newsletter icon

Sign Up For Our Newsletter

Stay informed by signing up for the Morning Briefing and other emails:

Recent Morning Briefings

  • Today, April 30
  • Wednesday, April 29
  • Tuesday, April 28
  • Monday, April 27
  • Friday, April 24
  • Thursday, April 23
More Morning Briefings
RSS Feeds
  • Podcasts
  • Special Reports
  • Morning Briefing
  • About Us
  • Donate
  • Staff
  • Republish Our Content
  • Contact Us

Follow Us

  • Instagram
  • YouTube
  • LinkedIn
  • Facebook
  • X
  • Bluesky
  • TikTok
  • RSS

Sign up for emails

Join our email list for regular updates based on your personal preferences.

Sign up
  • Editorial Policy
  • Privacy Policy

© 2026 KFF